This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Shipp, N. G. Articles by Hendrix, M. Search for Related Content PubMed PubMed Citation Articles by Shipp, N. G. Articles by Hendrix, M.

Characterization of Experimental Mitoxantrone Cardiotoxicity and Its Partial Inhibition by ICRF-187 in Cultured Neonatal Rat Heart Cells¹

Departments of Pharmacology [N. G. S., R. T. D., D. S. A.], Pathology [B. V. D.], and Anatomy [M. H.], College of Medicine, University of Arizona, Tucson, Arizona 85724

Mitoxantrone cardiotoxicity was investigated in isolated neonatal rat heart myocytes treated for 3 h in the presence or absence of the metal chelator ICRF-187. Electron microscopy studies of mitoxantrone-treated myocytes showed disorganized myofibrillar structures, swollen mitochondria, and extensive vacuolization. Cardiotoxicity, reflected as the ratio of intracellular ATP/protein and the loss of spontaneous beating, was only partially reduced by continuous ICRF-187 concentrations up to 50 µg/ml. ICRF-187 induced myocyte protection which was dependent on the dose and duration of exposure. ICRF-187 also reduced the cardiotoxicity of doxorubicin to a lesser extent and reduced the toxicity of a postulated cyclic mitoxantrone metabolite. However, the cardiotoxicity of ametantrone, a nonmetal-binding analogue of mitoxantrone, was unaltered with ICRF-187. The antitumor activity of mitoxantrone was unaltered by ICRF-187 in human tumor cells and in P-388-bearing mice. In addition, ICRF-187 allowed for 50% greater cumulative dosing in normal mice that, nonetheless, showed extensive histological heart damage 7 wk after dosing. These studies show that ICRF-187 provides partial protection from mitoxantrone cardiotoxicity in vitro without impairing the drug's antitumor activity in vitro or in vivo. This facilitates greater cumulative drug dosing in normal mice. The postulated mechanism of cardioprotection is metal chelation, because ICRF-187 did not alter the toxicity of a nonchelating mitoxantrone analogue.

¹ Supported in part by a grant from Lederie Laboratories, Pearl River, NY, and by Grants CA 17094 and 31078 from the Department of Health and Human Services, National Cancer Institute, NIH, Bethesda, MD, and from the Elsa U. Pardee Foundation.

² To whom requests for reprints should be addressed.

Received 6/ 4/92. Accepted 11/16/92.